Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Inovio Pharmaceuticals Inc INO

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP... see more

NDAQ:INO - Post Discussion

View:
Post by 7Twiggy on Jan 29, 2021 5:20pm

Repost

Repost from Reddit - INOVIO is a company that is working tirelessly to save lives from COVID-19 but has been relentlessly bullied by wall street and short attacked in coordination with the likes of Andrew Left of Citron recently and Adam Feurerstein from the Street in the past just about every time the company releases a good PR. Backed by the likes of the US DOD (for the current DNA based COVID-19 vaccine INO-4800) and DARPA (for a separate futuristic DNA based monoclonal antibody treatment vaccine for COVID-19) and just finishing up Phase 2, Inovio will begin phase 3 upon FDA approval of dosage arms from phase 2 data. Both phase 2/3 are fully funded by the DOD. In parallel they are finishing up a fully funded phase 2/3 trial in China through a company called Advaccine. Seeking EUA and BLA approval from the FDA or other, Inovio’s manufacturing consortium which is already in production and at the ready for mass production consists of Richter Helms, Ology, Thermo Fisher, Kanaka Eurogentec with more to be expected. Inovio has an extremely compelling platform with many advantages over the first generation vaccines which have received EUA. Inovio’s phase 1 COVID-19 vaccine published in the Lancet showed 100% immunogenicity in all patients and only mild grade 1 side effects but best of all has great thermostability and requires no superfreezers! The vaccine lasts 1 year in normal room temperature and 5 years in a regular refrigerator unlike the single digit hours shelf life afforded by their RNA vaccine counterparts. The DNA based platform has also shown amazing best ever results for GBM brain cancer and HPV related cancer and disease. Go to r/Inovio for info on that.

But here in lies the opportunity which I offer for your consideration on r/wallstreetbets, $INO r/inovio is in the top 20 heavily shorted list and is the only COVID-19 play. But it is NOT ON THE RESTRICTED LIST of the brokers!

Inovio was Andrew Left’s Citron top short of 2020. His hit pieces were almost criminally misleading and myself and many others honestly believe he should have been sued.

Consider getting in on the hit explosion boom that will be Inovio. I’d like to see poetic justice served on the shorts like Andrew Left and give them more of what they deserve. Help make it happen for the benefit of the world. Too many people I know are dying of COVID-19 and cancer. A company I consider will be the biotech stock of the millennium is working tirelessly because patients can’t wait. Peace and thanks for taking time to read this
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities